Literature DB >> 8025209

Intervention therapies for insulin-dependent diabetes.

A Muir1, D A Schatz, P Pozzilli, N K MacLaren.   

Abstract

Treatment of insulin-dependent diabetes remains problematic since there continues to be high rates of morbidity and mortality among affected patients. Good outcomes are most likely to be more common among patients who maintain endogenous insulin reserves for the longest time following diagnosis. The disease process can now be identified in its early, pre-symptomatic stages and thus, the time has come for the investigation of preventive therapies through multicenter clinical trials. A wide variety of strategies are available and their choice should be dependent on the pathogenic stage of disease at which treatment is initiated. This stage-specific approach to prevention is discussed with a particular focus on those therapies that will soon be tested in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8025209     DOI: 10.3109/08916939309014650

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  1 in total

1.  Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).

Authors:  P Pozzilli; N Visalli; A Signore; M G Baroni; R Buzzetti; M G Cavallo; M L Boccuni; D Fava; C Gragnoli; D Andreani
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.